The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

The Ministry of Health (SSA) reported a significant increase in whooping cough cases in Mexico during the first two months of ...

Discover effective homeopathic remedies for acute, subacute, and chronic coughs. Learn how personalized treatments can ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

Trevi Therapeutics (TRVI)has completed enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. Topline results continue ...

Trevi Therapeutics (TRVI) stock has rocketed up over 63% in the past week on news that recent clinical trials have shown promising results. The ...

Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it tries to close the gap with Merck & Co's rival drug gefapixant.

"The completion of enrollment in the Phase 2b CORAL trial is a significant milestone in the development of Haduvio for patients with idiopathic pulmonary fibrosis suffering from chronic cough ...

Trevi Therapeutics’ stock value has shot up more than 53% after its investigational therapy Haduvio (nalbuphine hydrochloride) reduced the frequency of coughing fits by 57% compared to placebo ...

Professor Jacky Smith "I am happy to share these robust positive results from our Phase 2a RIVER trial in refractory chronic cough which has been a difficult-to-treat indication with no approved ...

New Haven, Connecticut Tuesday, March 11, 2025, 18:00 Hrs [IST] ...